Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) announced Sept 18, 2017 that it had received total proceeds of $11,895,298 from the exercise of an aggregate of 19,185,965 warrants, which puts its cash position at $45 million. Shares of ABCN reacted this morning, rising over 1%. We reported in August on...
Geron Corporation (NASDAQ:GERN) is due to hold its annual meeting of shareholders on May 9, 2017, at 4:00 pm, PDT. The company has invited all stockholders to attend the meeting, which would be held at its office location, at 149 Commonwealth Drive, Menlo Park, California. Added to this, shareholders...
Jaguar Animal Health Inc (NASDAQ:JAGX) has announced the signing of a distribution agreement, with JP Equine Services. The agreement would cover two non-prescription products from the company and would be distributed in Japan. Neonorm Foal and Neonorm Calf, the products in question, are natural, clinically tested, non-drug products that...
MannKind Corporation (NASDAQ:MNKD) has announced that it would be releasing its financial results for the 1Q2017 on May 10, 2017. The release of the financial statements would be shortly followed by a conference call, by the management, to discuss the results. The conference call is scheduled for 5:00 pm,...
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) recently announced that it would be exercising a 1-for-10 reverse stock split, of all outstanding shares of the company’s common stock. Moreover, RNN would also exercise a corresponding proportional reduction in the number of authorized capital shares of the company, as well. The action is...
Protalix Biotherapeutics Inc (NYSEMKT:PLX) has announced that it would be releasing its financial results for the 1Q2017, as well as a corporate update, on May 10, 2017. The company has also stated that it would hold a conference call, on the same day. A replay of the call would...
RepliCel Life Sciences Inc (OTCMKTS:REPCF) has announced that it has been awarded a key patent for its technology, in the US. The company noted that the patent covers significant components of their multi-needle dermal injection device. The technology was developed after REPCF, while developing treatments for baldness and sun...
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a...
Keryx Biopharmaceuticals (NASDAQ:KERX) is all set to announce its Q1 2017 results next week. Last quarter, the company has recorded exceptional sales number of Auryxia which came at $8.2 million versus $4.8 million in Q4 2015. The company started registering revenue under the ex-factory process, or upon shipment from sales...
We are going to take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As...